New drug cocktail aims to crush resistant leukemia
NCT ID NCT06466122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining pirtobrutinib and venetoclax can eliminate signs of cancer in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has stopped responding to standard BTK inhibitors. About 30 adults currently taking ibrutinib, acalabrutinib, or zanubrutinib but with worsening disease will receive the two oral drugs. The main goal is to see how many achieve undetectable minimal residual disease in blood and bone marrow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for CLL/SLL patients whose cancer has stopped responding to standard BTK inhibitors.
What could go wrong
This is a small, early-phase trial with only 30 participants. The combination may not work for everyone, and side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-••••